Dr. Lal Path Labs Ltd. has informed the Exchange regarding Allotment of 82750 Shares.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.8 pts more than Nifty Smallcap 250 and 12.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Lal PathLabs reported FY26 consolidated revenue of ₹27,629 million, up 12.2% from ₹24,614 million in FY25. Profit after tax stood at ₹5,098 million versus ₹4,922 million in FY25, with basic EPS of ₹30.24 (vs ₹29.24 restated). The Board approved a final dividend of ₹4 per share for FY26, taking total dividend for the year to ₹20.5 per share. The company acquired 100% stake in Shahbazkers Diagnostic Centre Private Limited and plans to incorporate a new wholly owned subsidiary in Dubai. Executive Chairman Dr. Arvind Lal and Independent Director Rajit Mehta were reappointed for five-year terms. The auditors issued an unmodified opinion on the financial statements.
Steady financial performance with ~12% revenue growth and maintained profitability margins. Dividend increase signals confidence. Expansion through acquisition and international subsidiary signals growth focus.